This podcast discusses monitoring patients who have been started on a new diabetes therapy, such as sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide 1 receptor agonists. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients.